Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071161 | 0.93 | EPHX2 (0.38) | EPHX2BDKRB1P2RX7PPARG | |
| SCHEMBL10070590 | 0.92 | EPHX2 (0.40) | EPHX2BDKRB1P2RX7PPARG | |
| SCHEMBL11908533 | 0.91 | BDKRB1 (0.43) | EPHX2BDKRB1P2RX7PPARG | |
| SCHEMBL10070739 | 0.91 | BDKRB1 (0.43) | EPHX2BDKRB1P2RX7PPARG | |
| SCHEMBL185831 | 0.91 | BDKRB1 (0.35) | EPHX2BDKRB1P2RX7PPARGCNR1 | |
| SCHEMBL16404396 | 0.91 | BDKRB1 (0.35) | BDKRB1CNR1 | |
| SCHEMBL11906030 | 0.90 | BDKRB1 (0.36) | EPHX2BDKRB1P2RX7 | |
| SCHEMBL673233 | 0.90 | BDKRB1 (0.36) | EPHX2BDKRB1P2RX7 | |
| SCHEMBL185861 | 0.89 | BDKRB1 (0.37) | EPHX2BDKRB1CNR1 | |
| SCHEMBL10071167 | 0.89 | BDKRB1 (0.37) | EPHX2BDKRB1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937073-B2 | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937073-B2 | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-2606042-B1 | DISUBSTITUTED TETRAHYDROFURANYL COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2606042-B1 | DISUBSTITUTED TETRAHYDROFURANYL COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2606042-A1 | DISUBSTITUTED TETRAHYDOFURANYL COMPOUNDS AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120208823-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120208823-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2012022795-A1 | DISUBSTITUTED TETRAHYDOFURANYL COMPOUNDS AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022795-A1 | DISUBSTITUTED TETRAHYDOFURANYL COMPOUNDS AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208823-A1 | New Compounds | ABCG2, SDHA, UGT2B7 | EPHX2 2637/4885BDKRB1 2809/4885P2RX7 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.